x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

OncoPharm

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

science

All Episodes

00:09:32

Nivo-AVD Approval

OncoPharm ·

2026/03/24

Nivolumab-AVD is finally approved for Hodgkin Lymphoma, and primary G-CSF prophylaxis is recommended (?) in the PI. Also, brief NOLA preview for HOPA attendees. The Big Easy Debate: sazerac or hurricane? Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

en

00:14:47

Tazemetostat Withdrawl and RECITE

OncoPharm ·

2026/03/19

Tazemetostat is withdrawn from the market due to a risk of secondary malignancies.RECITE asks if romiplostim improves platelet counts for patients on oxaliplatin-based regimens with thrombocytopenia. Spoiler - yes it does, but does that make a difference? Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

en

00:12:47

FDA Approval Updates Galore

OncoPharm ·

2026/03/12

Lots of FDA approval updates to discuss from the past few weeks:-Zongertinib gets approved in 1st line setting for ERBB2 TKD mutated metastatic NSLCLC -Encorafenib approval with cetuximab + FOLFOX -Teclistamab + Daratumumab approved in 2nd line setting for r/r multiple myeloma -Acalabrutinib + venetoclax (but NOT acalabrutinib + venetoclax + obinutuzumab) is approved for CLL Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm

en

00:18:00

BR.31 & ASCO GU '26

OncoPharm ·

2026/03/05

This week discuss BR.31 trial of adjuvant durvalumab in NSCLC and put it into the context of the positive studies with atezolizumab and pembrolizumab. We also highlight 2 notable presentations at ASCO GU 2026 on perioperative enfortumab vedotin + pembrolizumab in cisplatin-eligible patients with resectable bladder cancer (KEYNOTE-B15) and advjuant pembrolizumab + belzutifan in RCC (LITESPARK-022)Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm

en

00:16:05

Rezatapopt and Colchicine for Trametnib/Dabrafenib...

OncoPharm ·

2026/02/26

An exciting new drug, rezatapopt, may be effective in restoring p53 activity in cancers - a possible major therapeutic breakthrough. Can colchicine treat pyrexia from tremetinib & dabrafenib use? This case series says - maybe: https://doi.org/10.1007/s00520-019-4654-2Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm

en

00:16:30

Perioperative Enortumab vedotin + Pembrolizumab

OncoPharm ·

2026/02/19

The EV-303 trial that led to the FDA approval of perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible bladder cancer patients in now published in NEJM. We discuss the results and ponder potential future changes to treating bladder cancer in the future.Urinary diversion surgeries: https://jamanetwork.com/journals/jamaoncology/fullarticle/2842595

en

00:12:34

Axi-Cel and 5-FU Label Changes

OncoPharm ·

2026/02/12

We have FDA changes to the labels of Axi-Cel (to allow for its use in primary CNS lymphoma) and 5-flourouracil (pre-treatment DPYD testing). Also, pembrolizumab nets another approval, this time in conjunction with paclitaxel for platinum-resistant ovarian cancer (limited to PD-L1 CPS of 1% of greater)

en

00:15:27

Core Communication Skills in Chemotherapy Education

OncoPharm ·

2026/02/05

A brief discussion of the Core Communication Skills* and how to incorporate them into a chemotherapy education session.*Rapport Building *Agenda Setting *Information Management *Active Listening *Addressing Feelings *Common Ground

en

00:15:44

PATINA

OncoPharm ·

2026/01/29

Reviewing the hot-off-the press publication of PATINA, palbociclib in HER-2 amplified breast cancer along with endocrine therapy and HER-2 targeted antibodies.

en

00:17:50

Sacituzumab govitecan + pembrolizumab and ASCO GI '26

OncoPharm ·

2026/01/22

We review the recent ASCENT-04/Keynote-D19 publication of sacituzuab govitecan + pembrolizumab for PD-L1 CPS of 10% and above TNBC compared to chemo + pembrolizumab alone.Also, a quick recap of ASCO GI earlier this month with mentions of zanidatamab and zolbetuximab. Finally, a check-in on The Pitt.

en

00:11:25

Oncology Drug Use Evolution

OncoPharm ·

2026/01/15

This episode is the 2nd chapter in a broader presentation about putting together the puzzle pieces of oncology drug use. This chapter discusses examples of how oncology drug use changes over time.Video & slides available at: https://youtu.be/Kxs0Xg9Ug_c?si=yOwEU1X-7mCPoQl5

en

00:15:08

2025 New Drug Review

OncoPharm ·

2026/01/08

A Holiday tradition like few other. Are we keeping, regifting, or returning new oncology drugs approved in 2025?

en

00:13:03

Bladder Cancer Updates & SC Amivantamab

OncoPharm ·

2025/12/18

Are we nearing the end of the Platinum Era in bladder cancer? A press release suggests enfortumab vedotin + pembrolizumab in a perioperative approach is better than the current standard of care: neoadjuvant cisplatin-based chemo followed by surgery. We eagerly await seeing this data.Also, a subcutaneous amivantamab/hyaluronidase formulation is approved, which offers a much lower risk of infusion reactions - but some chances for dosing errors based on weights and available dosage forms.

en

00:29:05

ASH 2025

OncoPharm ·

2025/12/11

ASH 2025 Highlights:MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma Paradigm: HMA + Ven vs. 7+3 or CPX-351 Denosumab safety & dosing in Multiply Myeloma and renal dysfunction Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?

en

00:15:33

DPYD Deficiency Testing

OncoPharm ·

2025/12/04

DPYD testing is more complicated than one would think! We talk through the steps to consider when initiating DPYD testing at your site. Resources below:Guide for implementing DPYD testing at your site: https://doi.org/10.1002/cpt.3567 CPIC Dosing Guidline: https://doi.org/10.1002/cpt.911 CPIC DPYD Resources: https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/

en

00:16:51

Cornucopia of Autumn Updates

OncoPharm ·

2025/11/26

We are back with lots of OncoPharm updates:1. The belantamab mafodotin REMS program details are available....and it's a lot. How will belantamab mafodin-regimens be used with the upcoming MAJESTIC-3 data of teclistamab-daratumumab? 2. The capecitabine label is updated and calls for pre-treatment DPYD testing 3. Daratumumab gets an FDA approval for high-risk smoldering myeloma based on the AQUILA study Critique of AQUILA: https://doi.org/10.1093/oncolo/oyaf216 4. A pertuzumab biosimilar

en

00:36:39

PGYNone: Dandelion Effect

OncoPharm ·

2025/11/20

Our 3rd and final installment in this Oncology Pharmacy Training Pathways mini-series discusses the PGYNone route. I am joined by Vineetha Thomas and Sheila Pierre to discuss their experiences in becoming oncology pharmacists, forgoing residency training, positions they held earlier in their career, and ultimately becoming thriving oncology pharmacists.This mini-series is supported by the ELO Collaborative, a fantastic training opportunity for those seeking get more oncology training outside

en

00:34:06

PGY1 Pathway: Road Trip!

OncoPharm ·

2025/11/13

Our 2nd installment in this Oncology Pharmacy Training Pathways mini-series discusses the PGY1 pharmacy residency route, without a PGY2 oncology residency. I am joined by Kayla Fry and Amber Burgess to discuss their experience to becoming oncology pharmacists. There are some similarities and differences in their paths to their current roles (and one It's-A-Small-World shared connection too!)This mini-series is supported by the ELO Collaborative, a fantastic training opportunity for those seeking

en

00:32:57

PGY2 Pathway: A Planned City

OncoPharm ·

2025/11/06

Our 1st installment in this Oncology Pharmacy Training Pathways mini-series discusses the PGY2 oncology pharmacy residency rout. I am joined by Brooke Adams and Sarah Wheeler to discuss our experience and PGY2 training. We discuss the pros/cons of pursuing a PGY2 oncology residency with the understanding that residency training (or additional residency) training isn't for everyone. This mini-series is supported by the ELO Collaborative, a fantastic training opportunity for those seeking get more

en

00:14:23

Tale from the Crypt: Belantamab Mafodotin

OncoPharm ·

2025/10/30

[Moving Trailer Voice] This Halloween: They always come back....The latest revival is belantamab mafodotin, FDA approved...again. After being vanquished in DREAMM3, it returned in DREAMM7 and even Daratumumab (in combination with Vd) couldn't overcome this blindingly effective drug (in combination with Vd). This pod reviews belantamab mafodotin's checkered past and wonders what the sequels may have in store for us.

en

420 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter